Organization | Hospital Regional Alta Especialidad Bajio

Hospital Regional Alta Especialidad Bajio Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Mexico (2007)

Organization Overview

First Clinical Trial

2007

NCT01410604

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Alternative names

Hospital Regional de Alta Especialidad | Hospital Regional de Alta Especialidad del BajÃo | Hospital Regional de Alta Especialidad del Bajio | Hospital Regional de Alta Especialidad del Bajío | Hospital Regional de Alta Especialidad del Bajìo

Active Ingredients

Drugs in Phase 4 Trials (5)

diclofenac (voltaren) (1 trial)

linagliptin (tradjenta) (5 trials)

metformin (glucophage) (3 trials)

sitagliptin (januvia) (2 trials)

tamsulosin (flomax) (1 trial)

Drugs in Phase 3 Trials (5)

chlorhexidine (hibitane) (1 trial)

COVID-19 convalescent plasma (1 trial)

empagliflozin (jardiance) (1 trial)

ethanol (1 trial)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Glucose Intolerance (Phase 4)

Hyperglycemia (Phase 3)

Insulin Resistance (Phase 4)

Neutropenia (Phase 3)

Prediabetic State (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 10